PT-141 (Bremelanotide) Global Regulatory Status

FDA Approval: Timeline and Basis

The FDA approved bremelanotide on June 21, 2019, under New Drug Application (NDA) 210557, making it the second drug ever cleared specifically for HSDD in premenopausal women [1]. Flibanserin (Addyi), a daily oral pill approved in 2015, was the first. Bremelanotide offered a different mechanism and dosing approach: a melanocortin-4 receptor (MC4R) agonist administered subcutaneously at least 45 minutes before anticipated sexual activity [2].

Approval rested on data from the two RECONNECT phase 3 trials, which enrolled a combined 1,247 premenopausal women with acquired, generalized HSDD [3]. In RECONNECT Study 301 (N=634), bremelanotide 1.75 mg increased the number of satisfying sexual events (SSEs) by a mean of 1.0 per month compared to 0.7 for placebo, while the co-primary endpoint of sexual desire, measured by the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) Item 13, improved by −0.7 points versus placebo (P<0.001) [3]. The RECONNECT Study 302 trial (N=613) replicated these results with statistically significant separation on both co-primary endpoints.

The FDA conducted its review under the standard pathway with a priority-review voucher redeemed by Palatin Technologies. An advisory committee meeting was not convened, and the agency issued a complete approval without a Risk Evaluation and Mitigation Strategy (REMS) requirement [1].

What the Vyleesi Label Specifies

The prescribing information for Vyleesi contains several constraints that distinguish it from other HSDD therapies [2]. Each dose is 1.75 mg delivered via a single-use autoinjector into the abdomen or thigh. Patients should administer the injection at least 45 minutes before anticipated sexual activity. The label limits use to no more than one dose within 24 hours and no more than eight doses per month.

A boxed warning is absent. The label does carry specific warnings for transient blood pressure elevation. In clinical trials, bremelanotide raised systolic blood pressure by an average of 3 mmHg and diastolic blood pressure by 1.5 mmHg, with peak effects occurring roughly 2 to 3 hours after dosing [2]. The FDA therefore contraindicated bremelanotide in patients with uncontrolled hypertension or known cardiovascular disease.

Nausea is the most commonly reported adverse event. In the RECONNECT trials, 40.0% of bremelanotide-treated women experienced nausea compared with 1.3% in the placebo group, though nausea severity diminished with repeated dosing [3]. The label also notes focal hyperpigmentation as a potential effect: darkening of the gums, face, or breasts occurred in approximately 1% of treated women and was sometimes irreversible [2].

The label explicitly states that Vyleesi is not indicated for the treatment of HSDD in postmenopausal women or in men [2]. This restriction reflects the enrollment criteria of the key trials, which exclusively studied premenopausal women aged 21 to 55.

Mechanism of Action and Pharmacology

Bremelanotide activates melanocortin receptors, primarily MC4R, within the central nervous system [4]. Unlike flibanserin, which modulates serotonin receptor activity through daily dosing, bremelanotide works through a peptide-based mechanism that allows on-demand administration. The drug is a synthetic cyclic heptapeptide analog of alpha-melanocyte-stimulating hormone (α-MSH).

After subcutaneous injection, bremelanotide reaches peak plasma concentration (Tmax) at approximately 1 hour [2]. Its elimination half-life is roughly 2.7 hours. The drug is metabolized through hydrolysis into amino acid fragments, and renal excretion accounts for approximately 64.8% of elimination [4]. No dose adjustment is required for mild-to-moderate hepatic impairment, but bremelanotide has not been studied in patients with severe hepatic or renal impairment [2].

MC4R activation in the medial preoptic area and other hypothalamic nuclei is thought to influence sexual arousal pathways independent of hormonal signaling [4]. This distinction is clinically relevant because bremelanotide does not alter circulating levels of estrogen, testosterone, or other sex hormones. Animal studies published in the Journal of Sexual Medicine showed that MC4R knockout mice did not respond to bremelanotide, confirming receptor specificity [5].

European and International Regulatory Status

Bremelanotide has not received marketing authorization from the European Medicines Agency (EMA). As of May 2026, no formal application for a Marketing Authorization Application (MAA) has been submitted to the EMA's Committee for Medicinal Products for Human Use (CHMP) [6]. The reasons are partly commercial and partly regulatory. HSDD diagnostic criteria differ between the DSM-5 (used in U.S. practice) and the ICD-11 (more commonly referenced in European regulatory submissions), and the European classification of female sexual dysfunction has historically favored the broader "hypoactive sexual desire dysfunction" category rather than the specific HSDD diagnosis [7].

Health Canada has not approved bremelanotide. No submission appears in the Drug Product Database or the Notice of Compliance listings. Similarly, the Australian Therapeutic Goods Administration (TGA) has not received an application for bremelanotide [8].

In Japan, the Pharmaceuticals and Medical Devices Agency (PMDA) has not reviewed bremelanotide. The drug is not included in Japan's National Health Insurance formulary. Sexual dysfunction therapeutics face particular regulatory friction in Japan, where flibanserin also remains unavailable.

The practical result is that Vyleesi remains a U.S.-only product. Patients outside the United States cannot legally obtain bremelanotide through conventional pharmacy channels. "PT-141" peptide products sold through compounding pharmacies or research-chemical suppliers in other countries are not equivalent to FDA-approved Vyleesi and carry significant quality and safety uncertainties.

Post-Market Safety Surveillance

The FDA Adverse Event Reporting System (FAERS) has accumulated several years of post-marketing data on bremelanotide since its 2019 approval [9]. The most frequently reported adverse events in FAERS align with the clinical trial profile: nausea (the leading complaint), injection-site reactions, headache, and flushing.

Blood pressure changes remain the primary cardiovascular safety signal under surveillance. The Sentinel System, FDA's active post-market monitoring platform, has flagged bremelanotide for ongoing cardiovascular outcome tracking, particularly given the contraindication in patients with uncontrolled hypertension [9]. No confirmed cases of myocardial infarction or stroke attributed to bremelanotide have appeared in published FAERS analyses through 2025.

Hyperpigmentation reports continue to accumulate post-market. A 2023 case series in the Journal of the American Academy of Dermatology described three women who developed persistent gingival and facial hyperpigmentation after 4 to 6 months of bremelanotide use, with incomplete resolution 12 months after discontinuation [10]. The mechanism likely involves MC1R cross-activation in melanocytes, a predictable off-target effect given bremelanotide's affinity for multiple melanocortin receptor subtypes [4].

No post-marketing requirement (PMR) studies were mandated at the time of approval, but the FDA requested that the manufacturer continue monitoring cardiovascular outcomes in a post-marketing commitment (PMC) observational study [1].

Compounding and Off-Label Considerations

PT-141 has a long history in the compounding pharmacy space that predates FDA approval of Vyleesi. Peptide suppliers and compounding pharmacies have sold bremelanotide under the "PT-141" designation for years, often marketing it for sexual dysfunction in both men and women, despite the lack of FDA-approved labeling for male HSDD or erectile dysfunction [11].

The FDA's 2023 guidance on compounding with bulk drug substances does not include bremelanotide on the agency's official "difficult to compound" list, but the existence of a commercially available FDA-approved product (Vyleesi) creates legal constraints [12]. Under section 503A of the Federal Food, Drug, and Cosmetic Act, compounding pharmacies may prepare patient-specific prescriptions, but they cannot compound copies of commercially available drugs without clinical justification for an individual patient. Section 503B outsourcing facilities face even stricter requirements.

Off-label prescribing of bremelanotide for male sexual dysfunction has been reported in clinical practice, though no phase 3 trial data support this use. Early phase 2 studies in men with erectile dysfunction showed some efficacy, but Palatin Technologies chose to pursue the female HSDD indication based on the commercial and regulatory environment at the time [11].

Comparison With Flibanserin Regulatory Path

Flibanserin's regulatory history provides useful context. The FDA rejected flibanserin twice (in 2010 and 2013) before approving it in 2015 under intense public advocacy pressure and with a mandatory REMS program due to hypotension and syncope risks when combined with alcohol [13]. Bremelanotide's path was comparatively smoother. It was not subject to an advisory committee vote, required no REMS, and reached the market without the "even the score" advocacy controversy that accompanied flibanserin [1].

Both drugs treat the same indication in the same population but differ in every other respect. Flibanserin requires daily oral dosing and carries alcohol interaction warnings. Bremelanotide is used on demand via injection and has no alcohol restriction. The RECONNECT trials showed that 40% of bremelanotide users experienced nausea versus roughly 11% of flibanserin users in the BEGONIA and SNOWDROP trials, but bremelanotide's nausea was transient and diminished over time [3][13].

From a scheduling perspective, neither drug is a controlled substance under the U.S. Controlled Substances Act. The DEA did not classify bremelanotide as having abuse potential, consistent with its mechanism of action and clinical trial data showing no withdrawal symptoms or dose-escalation behavior [2].

Intellectual Property and Market Exclusivity

Palatin Technologies holds the foundational patents on bremelanotide's composition and use. The Orange Book lists several patents associated with NDA 210557, with expiration dates extending through the late 2020s [14]. Pediatric exclusivity was not pursued, as HSDD is not a pediatric condition. No Paragraph IV ANDA filings for generic bremelanotide have appeared in FDA records as of May 2026.

AMAG Pharmaceuticals originally held the marketing rights but was acquired by Covis Pharma Group in 2020. Covis assumed commercial responsibility for Vyleesi in the U.S. market. Sales have been modest. Vyleesi generated approximately $8.2 million in net revenue during its first full year on the market, constrained by limited insurance coverage, the injection route of administration, and patient reluctance around self-injection for a sexual health product [14].

The combination of patent protection, limited commercial uptake, and no international filings suggests that generic competition or international availability will not materialize before the late 2020s at the earliest.

What Prescribers and Patients Should Know

Clinicians prescribing bremelanotide should confirm that the patient meets the labeled indication: premenopausal woman with acquired, generalized HSDD not explained by a medical or psychiatric condition, relationship factors, or medication effects [2]. Blood pressure should be measured at baseline and monitored during treatment, particularly in patients with pre-existing cardiovascular risk factors.

Patients should be counseled on three key points. First, nausea is expected but typically diminishes after the first few doses. Anti-emetic pretreatment is not addressed in the label but has been described in clinical practice. Second, the 8-dose monthly ceiling exists because long-term cardiovascular effects above this frequency have not been studied [2]. Third, hyperpigmentation may occur and may not fully reverse after stopping the medication [10].

For patients outside the United States who are seeking bremelanotide, no regulatory pathway currently exists. The recommended approach is to consult with a licensed prescriber about available alternatives or, where telehealth regulations permit, to explore U.S.-based prescribing options that can ship to jurisdictions allowing personal importation of prescription medications.

The most recent FDA safety communication regarding bremelanotide (dated October 2024) reiterated the cardiovascular contraindications and provided no new safety signals beyond the original labeling [9].